Clinical trials: Other Endocrine/Nutritional/Metabolic Disorder
- Condition Other Endocrine/Nutritional/Metabolic Disorder
- Funder type Industry (pharma, biotech, devices)
Diabetes Mellitus Type 2
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
This 2 arm study will compare the effects of aleglitazar and Actos, added to preexisting oral antihyperglycemic therapy and/or diet and exercise, on renal function in patients with type 2 diabetes, and normal or mildly impaired…
- Trial name
- NCT00461006
- Testing
- Actos, aleglitazar
- Where
- 52 sites in United States, Mexico and 3 more
- Volunteers
- 176 people
- Sponsor
- Hoffmann-La Roche
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia
The purpose of this study is to investigate the glycaemic control and other clinical parameters in adult patients previously treated with basal insulin (with or without OADs) and switched to IDegLira in real-world clinical…
- Trial name
- SPIRIT (NCT05324462)
- Testing
- IDegLira
- Where
- 6 sites in Colombia
- Volunteers
- 175 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Comparison Evaluation of Blood Glucose Meter Systems in a Clinical Setting
The purpose of this study was to test the performance of an investigational Bayer Blood Glucose (BG) meter and five additional Blood Glucose Monitoring Systems (BGMSs).
- Trial name
- NCT01614613
- Testing
- Bayer G3 / Tatsu System, Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips, Freestyle Lite® Meter and Test Strips with ZipwikTM tabs
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Ascensia Diabetes Care
Diabetes Mellitus, Type 2, Liver Diseases
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders
This is a prospective, multicentric, non-treatment study to build and validate a portable, non-invasive smart breath analyzer that can screen underlying health issues using exhaled breath.
- Conditions
- Diabetes Mellitus, Type 2, Liver Diseases, Kidney Diseases, Lung Diseases
- Trial name
- RESPYR-SBA (NCT07646015)
- Where
- India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Respyr
Diabetes Mellitus, Type 2
Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents
The purpose of this study is to compare the incidence of diabetic ketoacidosis (DKA) among participants diagnosed with type 2 diabetes mellitus (T2DM) and pair-matched on exposure propensity scores for new use of any…
- Trial name
- NCT02636192
- Testing
- No Intervention
- Volunteers
- 200,000 people
- Sponsor
- Janssen Research & Development, LLC
Other Endocrine/Nutritional/Metabolic Disorder
Nutritional Supplement Impact on Metabolic Parameters
This open label study seeks to study the effects of a nutritional supplement on inflammatory markers, metabolic parameters, and safety in subjects compared to baseline after taking supplement for 2 and 4 months.
- Trial name
- NCT02349555
- Testing
- Nutritional Supplement Blend
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM
This study was designed as a non-interventional, single-group, open-label, multicenter observational study for patients with type 2 diabetes in the real world clinical setting.
- Trial name
- SSUG (NCT04267601)
- Testing
- Anagliptin
- Where
- South Korea
- Volunteers
- 2,448 people
- Sponsor
- JW Pharmaceutical
Diabetes, Diabetes Mellitus, Type 2
Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics
This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins
- Trial name
- NCT00697450
- Testing
- insulin detemir
- Where
- Czechia
- Volunteers
- 206 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
The purpose of this study is to compare the incidence hospitalization for severe hypersensitivity and cutaneous reactions among patients with type 2 diabetes who are new users of saxagliptin and those who are new users of other…
- Trial name
- NCT01086319
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
The purpose of this study is to compare the incidence of hospitalization with acute liver failure among patients with type 2 diabetes who are new users of Saxagliptin and those who are new users of other oral antidiabetic drugs.
- Trial name
- NCT01086293
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1C (HbA1c) reduction in participants with type 2 diabetes mellitus (T2D) who have inadequate…
- Trial name
- SOTA-INS (NCT03285594)
- Testing
- Sotagliflozin, Insulin glargine (HOE901), Oral Antidiabetes Drugs (OADs)
- Where
- 106 sites in United States, Bulgaria and 6 more
- Volunteers
- 571 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.
- Trial name
- NCT00147758
- Testing
- Colesevelam hydrochloride
- Where
- 47 sites in United States, Mexico and 1 more
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes
Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)
This observational retrospective study will describe characteristics of patients with type 2 diabetes mellitus (T2DM) who were initiating use or treatment with sodium-glucose co-transporter-2 (SGLT-2) inhibitors and other…
- Trial name
- NCT03694470
- Where
- Russia
- Volunteers
- 10,000 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice.
- Trial name
- A1chieve® (NCT00869908)
- Testing
- insulin aspart, insulin detemir, biphasic insulin aspart
- Where
- 22 sites in Algeria, Argentina and 20 more
- Volunteers
- 66,726 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e.
- Trial name
- SUSTAIN™ 6 (NCT01720446)
- Testing
- semaglutide
- Where
- 253 sites in United States, Algeria and 19 more
- Volunteers
- 3,297 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes.
- Trial name
- REALYSE (NCT05035082)
- Testing
- semaglutide, oral glucose-lowering medications (commercially available)
- Where
- 25 sites in United States
- Volunteers
- 1,018 people
- Sponsor
- Novo Nordisk A/S
Hypoparathyroidism, Osteoporosis
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
The purpose of this study is to characterize and compare the pharmacokinetics of hPTH(1 34) after treatment with modified oral formulations (EBP11, EBP11-F1, EBP11-F2, EBP11-F4, EBP11-F5 and EBP22) versus three dose levels of…
- Conditions
- Hypoparathyroidism, Osteoporosis, Fractures, Bone, Other Disease
- Trial name
- NCT05965167
- Testing
- EBP05, Forteo 0.02 mg, EBP11
- Where
- Israel
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Entera Bio Ltd.